Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability.
Keywords: Signet ring cell carcinoma; chemotherapy; pancreatic cancer; pancreaticoduodenectomy.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.